Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes

Abstract We investigated the survival of female patients with pre-existing type 2 diabetes (T2D) diagnosed with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) of breast, in relation to the use of metformin, other antidiabetic medication (ADM) and statins. The study cohort consi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mayu Hosio, Elina Urpilainen, Ari Hautakoski, Mikko Marttila, Martti Arffman, Reijo Sund, Anne Ahtikoski, Ulla Puistola, Esa Läärä, Peeter Karihtala, Arja Jukkola
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0b4d4abd0eaf4665929c979a0ba8d789
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0b4d4abd0eaf4665929c979a0ba8d789
record_format	dspace
spelling	oai:doaj.org-article:0b4d4abd0eaf4665929c979a0ba8d7892021-12-02T15:53:10ZAssociation of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes10.1038/s41598-021-88488-x2045-2322https://doaj.org/article/0b4d4abd0eaf4665929c979a0ba8d7892021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88488-xhttps://doaj.org/toc/2045-2322Abstract We investigated the survival of female patients with pre-existing type 2 diabetes (T2D) diagnosed with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) of breast, in relation to the use of metformin, other antidiabetic medication (ADM) and statins. The study cohort consisted of 3,165 women (2,604 with IDC and 561 with ILC). The cumulative mortality from breast cancer (BC) and from other causes was calculated using the Aalen-Johansen estimator. The cause-specific mortality rates were analysed by Cox models, and adjusted hazard ratios (HRs) were estimated for the use of different medications. No evidence of an association of metformin use with BC mortality was observed in either IDC (HR 0.92, 95% confidence interval [CI] 0.64–1.31) or ILC (HR 0.68, 95% CI 0.32–1.46) patients, when compared to other oral ADMs. The mortality from other causes was found to be lower amongst the IDC patients using metformin (HR 0.64, 95% CI 0.45–0.89), but amongst ILC patients the evidence was inconclusive (HR 1.22, 95% CI 0.64–2.32). Statin use was consistently associated with reduced mortality from BC in IDC patients (HR 0.77, 95% CI 0.62–0.96) and ILC patients (HR 0.59, 95% CI 0.37–0.96), and also mortality from other causes in IDC patients (HR 0.81, 95% CI 0.67–0.96) and in ILC patients (HR 0.66, 95% CI 0.43–1.01). We found no sufficient evidence for the possible effects of metformin and statins on the prognosis of BC being different in the two histological subtypes.Mayu HosioElina UrpilainenAri HautakoskiMikko MarttilaMartti ArffmanReijo SundAnne AhtikoskiUlla PuistolaEsa LääräPeeter KarihtalaArja JukkolaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mayu Hosio Elina Urpilainen Ari Hautakoski Mikko Marttila Martti Arffman Reijo Sund Anne Ahtikoski Ulla Puistola Esa Läärä Peeter Karihtala Arja Jukkola Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes
description	Abstract We investigated the survival of female patients with pre-existing type 2 diabetes (T2D) diagnosed with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) of breast, in relation to the use of metformin, other antidiabetic medication (ADM) and statins. The study cohort consisted of 3,165 women (2,604 with IDC and 561 with ILC). The cumulative mortality from breast cancer (BC) and from other causes was calculated using the Aalen-Johansen estimator. The cause-specific mortality rates were analysed by Cox models, and adjusted hazard ratios (HRs) were estimated for the use of different medications. No evidence of an association of metformin use with BC mortality was observed in either IDC (HR 0.92, 95% confidence interval [CI] 0.64–1.31) or ILC (HR 0.68, 95% CI 0.32–1.46) patients, when compared to other oral ADMs. The mortality from other causes was found to be lower amongst the IDC patients using metformin (HR 0.64, 95% CI 0.45–0.89), but amongst ILC patients the evidence was inconclusive (HR 1.22, 95% CI 0.64–2.32). Statin use was consistently associated with reduced mortality from BC in IDC patients (HR 0.77, 95% CI 0.62–0.96) and ILC patients (HR 0.59, 95% CI 0.37–0.96), and also mortality from other causes in IDC patients (HR 0.81, 95% CI 0.67–0.96) and in ILC patients (HR 0.66, 95% CI 0.43–1.01). We found no sufficient evidence for the possible effects of metformin and statins on the prognosis of BC being different in the two histological subtypes.
format	article
author	Mayu Hosio Elina Urpilainen Ari Hautakoski Mikko Marttila Martti Arffman Reijo Sund Anne Ahtikoski Ulla Puistola Esa Läärä Peeter Karihtala Arja Jukkola
author_facet	Mayu Hosio Elina Urpilainen Ari Hautakoski Mikko Marttila Martti Arffman Reijo Sund Anne Ahtikoski Ulla Puistola Esa Läärä Peeter Karihtala Arja Jukkola
author_sort	Mayu Hosio
title	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes
title_short	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes
title_full	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes
title_fullStr	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes
title_full_unstemmed	Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes
title_sort	association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0b4d4abd0eaf4665929c979a0ba8d789
work_keys_str_mv	AT mayuhosio associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT elinaurpilainen associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT arihautakoski associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT mikkomarttila associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT marttiarffman associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT reijosund associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT anneahtikoski associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT ullapuistola associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT esalaara associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT peeterkarihtala associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes AT arjajukkola associationofantidiabeticmedicationandstatinswithsurvivalfromductalandlobularbreastcarcinomainwomenwithtype2diabetes
_version_	1718385492932689920

Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes

Ejemplares similares